SCHEMBL190963

SCHEMBL190963

CC(C)(C)OC(=O)N1CCC(CSc2cnc(Nc3nc(-c4ccccc4)cs3)cc2Oc2cccc3ncccc23)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.40
USP30 Q70CQ3 2/20 0.38
PTPRB P23467 1/20 0.37
GBA1 P04062 1/20 0.36
KDM1A O60341 1/20 0.36
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
SYK P43405 1/20 0.35
ROCK1 Q13464 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
MET P08581 1/20 0.34
KDM4E B2RXH2 2/20 0.34
PKM P14618 1/20 0.34
MAPT P10636 2/20 0.34
YAP1 P46937 1/20 0.34
HTR6 P50406 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL192811 0.92 GCK (0.42) GCKSYKROCK1MAPT
SCHEMBL225130 0.91 GCK (0.41) GCKADORA2AADORA2BSYKKDM4E
SCHEMBL12305701 0.84 NPC1 (0.39) GCKROCK1MAPT
SCHEMBL2461010 0.84 GCK (0.43) GCKSYK
Hydrochloric Acid SCHEMBL191877 0.83 NPC1 (0.38) GCKROCK1MAPT
SCHEMBL190808 0.79 NPC1 (0.40) KDM4EMAPT
SCHEMBL225129 0.78 GCK (0.37) GCKSYK
SCHEMBL12305702 0.75 CACNA2D1 (0.38) GCK
Hydrochloric Acid SCHEMBL190355 0.74 CACNA2D1 (0.37) GCK
SCHEMBL191010 0.73 NPC1 (0.48) PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 GCK 2/4885USP30 4174/4885PTPRB 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.